Somanetics (SMTS) Tops Q2 View; Reaffirms FY08 Sales Guidance
More News related to SMTS
- Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
- Somanetics Corp. (SMTS) Reports Q3 EPS of $0.23, Beats by 3c; Guides FY08 Sales
- Citi Downgrades Somanetics (SMTS) to Hold
- Somanetics (SMTS) Announces Share Repurchase Program Increased By $15 Million
- Somanetics (SMTS) Tops Q2 View; Reaffirms FY08 Sales Guidance
More News related to Earnings
- Post Properties (PPS) Announces Reduction In Quarterly Dividend To 20c, CIO Departure and New Stock Buyback Of Up To $200M
- Roberts Realty Investors (RPI) Increases Stock Repurchase Program
- United American Healthcare (UAHC) Approves $1 Million Stock Buyback
- Quidel Corporation (QDEL) Extends Current Stock Buyback Plan
- Quidel (QDEL) Adds $25M to Buyback Program
Somanetics Corporation (Nasdaq: SMTS) reports Q2 EPS of $0.21, 5 cents better than the analyst estimate of $0.16. Revenues for the quarter were $12.7 million, versus the consensus of $11.02 million.
Reaffirms its previously issued FY08 guidance of revs in the range of $46.2-$50 million, versus the consensus of $45.79 million.
Somanetics Corporation engages in the development, manufacture, and marketing of medical devices primarily in the United States.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.83Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
